A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 02 Apr 2018
At a glance
- Drugs Benralizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms SOLANA
- Sponsors AstraZeneca
- 29 Mar 2018 Planned End Date changed from 20 Aug 2018 to 3 Aug 2018.
- 29 Mar 2018 Planned primary completion date changed from 20 Aug 2018 to 3 Aug 2018.
- 29 Mar 2018 Status changed from recruiting to active, no longer recruiting.